Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia.

Published

Journal Article (Letter)

Full Text

Duke Authors

Cited Authors

  • Giles, F; Rizzieri, D; Ravandi, F; Swords, R; Jacobsen, TF; O'Brien, S

Published Date

  • April 2012

Published In

Volume / Issue

  • 36 / 4

Start / End Page

  • e71 - e73

PubMed ID

  • 22226018

Pubmed Central ID

  • 22226018

Electronic International Standard Serial Number (EISSN)

  • 1873-5835

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2011.12.010

Language

  • eng

Conference Location

  • England